Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of oral edaravone in ALS (MT-1186-A-301)
jRCT2041220069Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Incidence of adverse events and adverse drug reactions. Started Oct 2022; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2041220069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220069.